Vistagen Therapeutics Files 8-K: Director/Officer Changes & More
Ticker: VTGN · Form: 8-K · Filed: Dec 3, 2025 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $450,000, $50,000, $4 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, filing
Related Tickers: VTGN
TL;DR
Vistagen 8-K: New directors, officers appointed, and comp plans updated. Keep an eye on leadership changes.
AI Summary
Vistagen Therapeutics, Inc. filed an 8-K on December 3, 2025, reporting events as of November 28, 2025. The filing includes information regarding the departure and election of directors, appointment of officers, and compensatory arrangements. It also covers Regulation FD disclosures and financial statements/exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensatory arrangements, can signal internal shifts that may affect company strategy and performance.
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- November 28, 2025 (date) — Earliest event reported date
- December 3, 2025 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
- 343 Allerton Ave. (address) — Principal executive offices
- South San Francisco, California (location) — City, State of principal executive offices
- 650-577-3600 (phone_number) — Registrant's phone number
FAQ
What specific changes were made regarding directors and officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
What is the date of the earliest event reported in this 8-K?
The earliest event reported is dated November 28, 2025.
What is the company's state of incorporation?
Vistagen Therapeutics, Inc. is incorporated in Nevada.
What are the company's principal executive offices?
The principal executive offices are located at 343 Allerton Ave., South San Francisco, California.
What other items are covered in this 8-K filing besides director and officer changes?
The filing also covers Regulation FD Disclosure and Financial Statements and Exhibits.
Filing Stats: 1,247 words · 5 min read · ~4 pages · Grade level 11.1 · Accepted 2025-12-03 16:47:31
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market
- $450,000 — e paid a starting annual base salary of $450,000 and will be eligible to participate in
- $50,000 — s amended. Mr. Tressler also received a $50,000 signing bonus, and will be eligible to
- $4 — term and an exercise price per share of $4.43, the closing price of the Company's
Filing Documents
- vtgn-20251128.htm (8-K) — 33KB
- vtgn8-k11282025ex101.htm (EX-10.1) — 59KB
- vtgn8-k11282025ex991.htm (EX-99.1) — 12KB
- vistagen_primary-logoxbluea.jpg (GRAPHIC) — 41KB
- 0001628280-25-055083.txt ( ) — 293KB
- vtgn-20251128.xsd (EX-101.SCH) — 2KB
- vtgn-20251128_lab.xml (EX-101.LAB) — 21KB
- vtgn-20251128_pre.xml (EX-101.PRE) — 12KB
- vtgn-20251128_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. A copy of the press release announcing Mr. Tressler's appointment is attached to this Current Report on Form 8-K as Exhibit 99.1. The information under this Item 7.01 and Exhibit 99.1 attached hereto are intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Index Exhibit No. Description 10.1 Indemnification Agreement by and between Vistagen Therapeutics, Inc. and Nick B. Tressler, dated December 1, 2025 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated December 1, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: December 3, 2025 By: /s/ Shawn K. Singh Shawn K. Singh President and Chief Executive Officer